Tirzepatide is a once-weekly injectable dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It works by increasing insulin production and lowering glucagon secretion, as well as targeting areas in the brain that regulate appetite and food intake. A small molecular modification allows the drug to last for weeks in the body (versus minutes for the natural hormone).
Frequently Asked Questions
Tirzepatide may increase the risk of thyroid tumors, including cancer. Tell your healthcare provider if you experience a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath, as these may be symptoms of thyroid cancer. Do not use Tirzepatide if you or a family member have had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not take Tirzepatide if you (or an immediate family member) have a history of MTC or MEN 2. Use caution if you have a history of pancreatitis, acute kidney injury, diabetic retinopathy, gallbladder disease, or if you have any sensitivity/allergy to Tirzepatide. Pregnant or breastfeeding women should not use Tirzepatide, and those planning to become pregnant should discontinue it 2 months before trying to conceive.
Most medications and foods are compatible with Tirzepatide, but you should always inform your provider of all drugs and supplements you are taking. Avoid situations that could lead to hypoglycemia and follow your provider's guidance on diet and alcohol while on this medication. (Additional specific provider guidance would be given case-by-case.)
